MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases. They currently have five programs in clinical development including three ocular indications, a salivary gland condition, and a Parkinson’s disease program. Their initial focus on diseases of the eye, salivary gland and central nervous system
…More is based on the significant unmet medical need coupled with the high potential gene therapy has to provide meaningful clinical benefit in these areas. With headquarters in New York and London, their global footprint provides them the opportunity to partner with leading institutions around the world, allowing them to deepen their understanding of diseases and their progression.